To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Once-Daily Boosted Atazanavir as Effective as Twice-Daily Boosted Lopinavir in Treatment-Naive HIV Patients: Presented at CROI URL: http://www.pslgroup.com/dg/21C8B2.htm Doctor's Guide February 6, 2008
By Maria Bishop BOSTON, MA -- February 6, 2008 -- Once-daily atazanavir boosted with ritonavir (ATV/r) is as effective as twice-daily lopinavir boosted with ritonavir (LPV/r) in treatment-naive patients with HIV who were also taking fixed-dose tenofovir/emtricitabine, according to study results presented here at the 15th Conference on Retroviruses and Opportunistic Infections (CROI). Lead author Jean-Michel Molina, MD, PhD, Head, Department of Infectious Diseases, St Louis Hospital, and Professor, Infectious Diseases, University of Paris - Diderot Paris 7, Paris, France, presented the study on February 4. Dr. Molina noted that ATV/r demonstrated similar efficacy, a lower incidence of gastrointestinal-related adverse events, and a significantly better lipid profile compared with LPV/r. The interim data from the ongoing, 96-week CASTLE study examined 883 treatment-naive patients with HIV who were randomized to receive either ATV/r (n = 440) or LPV/r (n = 443). At week 48, mean CD4 increases from baseline were 203 and 219 cells/mm3 for ATV/r and LPV/r, respectively. Fewer patients on ATV/r (2%) than on LPV/r (7%) initiated lipid-lowering therapy. The rates of patients with ratios greater than 5 for triglycerides to high-density lipoprotein at week 48 were 12% and 20% in the ATV/r and LPV/r groups, respectively. Patients on ATV/r had a lower incidence of grade 2 to 4 treatment-related adverse events than those on LPV/r (diarrhea, 2% vs 11%; nausea, 4% vs 8%). Both regimens were generally well tolerated, with low rates of treatment discontinuation. Dr. Molina concluded that ATV/r is an appropriate therapeutic option for treatment-naive patients, and is highly effective in achieving virus undetectability in patients with advanced disease. Funding for the CASTLE study was provided by Bristol Myers Squibb. [Presentation title: Efficacy and Safety of Once-Daily Atazanavir/Ritonavir Compared to Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine in ARV-Naive HIV-1-Infected Subjects. The CASTLE Study, 48-Week Results. Abstract 37] --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.